A Trial Comparing the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily in Insulin-naive Subjects With Type 2 Diabetes Mellitus When Using Two Different Titration Algorithms (BOOST: SIMPLE USE).

Next Previous
Trial Profile

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily in Insulin-naive Subjects With Type 2 Diabetes Mellitus When Using Two Different Titration Algorithms (BOOST: SIMPLE USE).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Insulin degludec/insulin aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BOOST; BOOST-SIMPLE-USE
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Jan 2016 Results published in the Diabetic Medicine
    • 04 Apr 2012 Actual patient number (276) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top